OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
May 02, 2023
Digital transformation to the Pharma 4.0 paradigm moves forward in process development and clinical and commercial manufacturing.
In this episode, Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.
May 01, 2023
Roger Viney, chief commercial officer at ICE Pharma, discusses the history and current use of bile acid therapeutics.
April 27, 2023
Webinar Date/Time: Friday, May 19, 2023 at 11am EDT| 10am CDT | 8am PDT
April 25, 2023
Aspect Biosystems and Novo Nordisk A/S have announced a collaboration, development, and license agreement to develop bioprinted tissue therapeutics.
The leaked study summary found that Carvykti (ciltacabtagene autoleucel) reduced disease progression by 74%.
April 24, 2023
BioChain has reached partnerships with NanoString and 10x Genomics to extend its spatial multiomics services.
April 22, 2023
Rafael Antunes, vice-president of Business Development Europe at Aurisco, speaks about his company's recent efforts in the field of oligonucleotides, its partnership with Cytiva, and its broader sustainability efforts.
April 20, 2023
Gregor Kawaletz, head of Oral Solid Dose Business Unit at Recipharm, discusses the immediate future of oral biologics
April 18, 2023
Moderna and Merck reported that a combination therapy involving pembrolizumab and an mRNA demonstrated a 44% reduction in recurrence or death in cancer patients compared to non-combination treatments.
